Navigation Links
Phylonix granted broad European patent for transplanting human cells into zebrafish
Date:12/18/2007

Cambridge, MA -- December 18, 2007 -- Phylonix Pharmaceuticals today announced that it recently received a broadly issued European patent EP 1 135 531 B1: Methods for Introducing Heterologous Cells into Fish. The patent, which has issued in key European countries, encompasses 68 claims, including transplanting stem cells, cancer cells and pathogens. In addition, neurons, chondrocytes, renal and hepatic cells can be transplanted in zebrafish and effects of growth factors or cytotoxic agents can be assessed. Claims also cover recovering cells for potential tissue engineering or transplantation applications. Many of these claims have issued previously in the United States and other countries.

This award complements our previously issued patents for assessing angiogenesis, apoptosis and toxicity in zebrafish, and use of high-throughput screening methods such as microplate analysis, commented Patricia McGrath, Phylonix President and Chief Executive Officer.

Cells that proliferate in their native environment also proliferate when transplanted into zebrafish; cells that are incapable of proliferating in their native environment usually do not proliferate in zebrafish.

Advantages of Zebrafish for Transplantation

Currently, the mouse is the model system of choice for cell transplantation assays. However, to prevent cell rejection, transplantation of human cells must be performed using immunosuppressed mice and these animals are expensive to develop and maintain. In comparison, cell transplantation in zebrafish larvae is simple and cost effective, and immunosuppression is not necessary.

There are several additional advantages of using zebrafish for transplantation assays. All essential components of vertebrate form and organ development are mimicked in the transparent zebrafish and their molecular basis is either identical or similar, underscoring the potential for use in research on human diseases. Due to the small size of zebrafish larvae, it is possible to rapidly analyze and or recover transplanted cells. Zebrafish larvae are transparent facilitating direct microscopic observation of a number of physiological processes within the cells. Zebrafish can be cultured in solution facilitating contacting transplanted cells with drugs or growth factors. Microliters of drug are required for zebrafish compared with milliliters per mouse. Standard microtiter plate readers can be used for measurement, making this format particularly attractive for high throughput drug screening. Phylonix and others have demonstrated that for many compounds, results in zebrafish correlate with results in other animal models as well as with results in humans.


'/>"/>

Contact: Edward O'Lear
ed.olear@phylonix.com
617-441-6700
Phylonix Pharmaceuticals
Source:Eurekalert

Related medicine news :

1. NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases
2. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
3. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
4. USC granted $8.4 million for autism research
5. Aida Granted Additional Anti-Cancer Patent
6. CME LLC Granted Five-Year Full Approval by the American Psychological Association
7. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
8. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
9. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
10. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
11. Broad-based group of physicians calls for improvement in stroke treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Fire Door Solutions, headquartered ... resource, from start to finish, for Life Safety compliance. These expanded services ... requested by the Joint Commission, and fire stopping reviews, inspections, and repairs. ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... enabled solutions and managed services today announced a strategic partnership with Five9 ... center market. , Altura, one of Avaya’s largest Platinum Business Partners, is ...
(Date:5/24/2016)... Atlanta, Georgia (PRWEB) , ... May 24, 2016 , ... ... in 1969 by the Church of Scientology and renowned professor of psychiatry Thomas Szasz, ... opening of its “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening ...
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading ... Unit® (CDU), a groundbreaking new product for pediatric dentistry , at AAPD 2016, ... San Antonio, TX May 26-29. The Concealed Delivery Unit keeps dental hand pieces and ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and clinical practice of radiosurgery, is recognizing five medical residents and students for ... stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
(Date:5/24/2016)... , May 24, 2016 Dutch surgeons ... best practices around the world and treat patients on a global ... Africa , Asia and the US ... with instant messaging and networking in a totally secure environment. ... in a war zone working together with a surgeon at Harvard ...
(Date:5/23/2016)... FLINT, Mich. , May 23, 2016 Diplomat ... the third annual Fellowship and Internship programs. The hands-on ... 12. The full-time, paid Fellowship ... Flint, Michigan . Fellows and interns are ... downtown Flint at the Riverfront ...
Breaking Medicine Technology: